Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A
Division of Nephrology, Ospedale di Lecco, Italy.
Lancet. 1991 Jun 1;337(8753):1299-304. doi: 10.1016/0140-6736(91)92977-a.
A multicentre, prospective trial was organised to clarify the role of protein restriction in the progression of chronic renal insufficiency (CRI). 456 adult patients were assigned either a low-protein diet (0.6 g/kg body weight daily; n = 226) or a "normal" controlled-protein diet (1.0 g/kg daily; n = 230) and were stratified into three groups (A-C) with increasing baseline plasma creatinine concentrations. Each patient was followed up for 2 years or until an endpoint (a doubling of the baseline plasma creatinine or a need for dialysis) was reached. The difference between the diet groups in cumulative renal survival defined by these endpoints (27 low-protein, 42 controlled-protein) was of borderline significance (p less than 0.06). The difference in renal survival between the low-protein and controlled-protein diet groups was of borderline significance in group A (0 vs 4 endpoints), significant in group B (10 vs 21 endpoints; p less than 0.025), and not significant in group C. There were no differences among the diet groups or subgroups in mean plasma creatinine concentrations, creatinine clearance, the slope of the plasma creatinine reciprocal, or mean blood pressures. Compliance was good in the controlled-protein group but poor for the low-protein diet: the difference in protein intake between the groups was substantially less than that required by the protocol. However, there was no correlation between the progression of renal failure and protein catabolic rate. These findings offer little, if any, support to the hypothesis that protein restriction retards CRI progression: careful medical care and a "normal" controlled protein intake also allow very slow progression of CRI.
一项多中心前瞻性试验旨在明确蛋白质限制在慢性肾功能不全(CRI)进展中的作用。456例成年患者被分配至低蛋白饮食组(每日0.6 g/kg体重;n = 226)或“正常”控制蛋白饮食组(每日1.0 g/kg;n = 230),并根据基线血浆肌酐浓度升高情况分为三组(A - C)。每位患者随访2年或直至达到终点(基线血浆肌酐翻倍或需要透析)。由这些终点定义的饮食组间累积肾脏生存率差异(低蛋白组27例,控制蛋白组42例)具有临界显著性(p小于0.06)。低蛋白饮食组与控制蛋白饮食组的肾脏生存率差异在A组具有临界显著性(0个终点对4个终点),在B组具有显著性(10个终点对21个终点;p小于0.025),在C组不具有显著性。饮食组或亚组在平均血浆肌酐浓度、肌酐清除率、血浆肌酐倒数斜率或平均血压方面无差异。控制蛋白组的依从性良好,但低蛋白饮食组较差:两组间蛋白质摄入量差异远小于方案要求。然而,肾衰竭进展与蛋白质分解代谢率之间无相关性。这些发现几乎没有支持蛋白质限制延缓CRI进展这一假说:精心的医疗护理和“正常”的控制蛋白质摄入量也会使CRI进展非常缓慢。